108 related articles for article (PubMed ID: 33253057)
1. Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer.
Saxby K; Nickson C; Mann GB; Park A; Bromley H; Velentzis L; Procopio P; Canfell K; Petrie D
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):847-857. PubMed ID: 33253057
[No Abstract] [Full Text] [Related]
2. Quality-of-life effects of screening mammography in Norway.
Zahl PH; Kalager M; Suhrke P; Nord E
Int J Cancer; 2020 Apr; 146(8):2104-2112. PubMed ID: 31254388
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program.
Rim SH; Allaire BT; Ekwueme DU; Miller JW; Subramanian S; Hall IJ; Hoerger TJ
Cancer Causes Control; 2019 Aug; 30(8):819-826. PubMed ID: 31098856
[TBL] [Abstract][Full Text] [Related]
4. The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort.
Saxby K; Nickson C; Mann GB; Velentzis L; Bromley HL; Procopio P; Canfell K; Petrie D
Aust N Z J Public Health; 2020 Jun; 44(3):219-226. PubMed ID: 32311194
[TBL] [Abstract][Full Text] [Related]
5. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. Mode of detection: an independent prognostic factor for women with breast cancer.
Hofvind S; Holen Å; Román M; Sebuødegård S; Puig-Vives M; Akslen L
J Med Screen; 2016 Jun; 23(2):89-97. PubMed ID: 26582492
[TBL] [Abstract][Full Text] [Related]
8. Factors related to breast cancer detection mode and time to diagnosis in Alberta, Canada: a population-based retrospective cohort study.
Yuan Y; Li M; Yang J; Elliot T; Dabbs K; Dickinson JA; Fisher S; Winget M
BMC Health Serv Res; 2016 Feb; 16():65. PubMed ID: 26892589
[TBL] [Abstract][Full Text] [Related]
9. Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study.
Strand F; Humphreys K; Cheddad A; Törnberg S; Azavedo E; Shepherd J; Hall P; Czene K
Breast Cancer Res; 2016 Oct; 18(1):100. PubMed ID: 27716311
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
[TBL] [Abstract][Full Text] [Related]
11. Tumour characteristics of bilateral screen-detected cancers and bilateral interval cancers in women participating at biennial screening mammography.
van Bommel R; Lameijer JRC; Voogd AC; Nederend J; Louwman MWJ; Setz-Pels W; Strobbe LJ; Tjan-Heijnen VCG; Duijm LE
Eur J Radiol; 2018 Nov; 108():215-221. PubMed ID: 30396659
[TBL] [Abstract][Full Text] [Related]
12. Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.
Prummel MV; Done SJ; Muradali D; Majpruz V; Brown P; Jiang H; Shumak RS; Yaffe MJ; Holloway CM; Chiarelli AM
Breast Cancer Res Treat; 2014 Sep; 147(2):389-99. PubMed ID: 25108740
[TBL] [Abstract][Full Text] [Related]
13. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
[TBL] [Abstract][Full Text] [Related]
14. Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
Defossez G; Quillet A; Ingrand P
BMC Cancer; 2018 Apr; 18(1):393. PubMed ID: 29625602
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
[TBL] [Abstract][Full Text] [Related]
17. Independent prognostic value of screen detection in invasive breast cancer.
Mook S; Van 't Veer LJ; Rutgers EJ; Ravdin PM; van de Velde AO; van Leeuwen FE; Visser O; Schmidt MK
J Natl Cancer Inst; 2011 Apr; 103(7):585-97. PubMed ID: 21350218
[TBL] [Abstract][Full Text] [Related]
18. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
Shen Y; Yang Y; Inoue LY; Munsell MF; Miller AB; Berry DA
J Natl Cancer Inst; 2005 Aug; 97(16):1195-203. PubMed ID: 16106024
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
